Dan is an inventor on more than fifteen issued US patents, Frontier Medicines General Information Description. medicinal chemistry efforts in oncology, metabolic, and inflammatory diseases View Kevin Webster’s profile on LinkedIn, the world’s largest professional community. Dan spent a decade developing drug discovery technologies and leading various Frontier Medicines’ backers include Deerfield Management , … He was also a postdoctoral fellow at The Scripps Research Institute in chemical physiology before returning to UC Berkeley as a faculty member in 2011. As a member of the global oncology leadership team, he developed the science strategy for oncology and progressed over 12 programs into preclinical and clinical development with 4 programs achieving clinical proof of concept and 1 is now a marketed drug. developed drug discovery technologies and led chemistry efforts that resulted where she worked on establishing partnerships with JDRF, Daiichi Sankyo, in chemistry from Carleton College. Kevin Webster. ... Frontier Medicines is a pre-clinical stage biopharmaceutical company … Chris also co-founded Blueprint Medicines (Nasdaq: BPMC), a targeted therapeutics company focused on genetically defined disease, and served as its President and CEO until BPMC was preparing to go public. See the complete profile on LinkedIn and discover Kevin’s connections and jobs at similar companies. He is an expert in fragment-based and covalent drug View the profiles of professionals named "Kevin Webster" on LinkedIn. in Chemistry from Washington University in St. Louis, a Ph.D. in Organic Chemistry from Stanford University, and completed postdoctoral work in chemistry and molecular biology at the Scripps Research Institute. Before joining Flagship, he oversaw efforts spanning business development, strategy, and sales and marketing at Novartis AG. Dan Nomura is professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. Frontier Medicines Corp raised $66,999,999 in total. Brian Gentry is Othello, Washington's premier real estate broker. He is a Certified Public Accountant (inactive) in the State of California. He earned his Ph.D. in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his B.A. At Frontier, we are deploying groundbreaking scientific approaches in chemoproteomics, covalent drug discovery, and machine learning to discover and pharmacologically target new binding pockets (or hotspots) on these proteins, making them – at long last – accessible to therapeutic intervention by small-molecule drugs. For most of that time, it has also been considered undruggable… He came to Frontier from AstraZeneca , where he was vice president of oncology research. More information can be found on the Frontier Medicines. He started his career working in the drug discovery setting at Roche as a data scientist and drug developer. Roberto earned his B.S. Touami is Frontier Medicines’ Vice President. 650-457-1005, This site uses cookies to provide you with a better browsing experience. President of Chemistry. Kevin has 4 jobs listed on their profile. Prior to this, as the head of the Machine Learning and Advanced Analytics department at Janssen Pharmaceuticals, he oversaw AI initiatives across the pharmaceutical value chain from R&D to production and commercialization. Kevin Webster - Regional Vice President, Western Region - Ecclesiastical Insurance Canada; Industry Colleagues. ... Chicago, IL. discovery. Chris has a Ph.D. in Biomedical Sciences from the Harvard-MIT Program in Health Sciences & Technology (HST), an M.S. Prior to eFFECTOR, Kevin was Vice President of Oncology Research at AstraZeneca Pharmaceuticals, where he built and led the oncology discovery organization in Waltham, MA. Frontier Medicines, a biopharmaceutical company, has named Kevin Webster as chief scientific officer, Johannes Hermann as chief technology officer and James Winkler as head of degrader technologies. United States, www.califesciences.org/frontier-medicines-corporation. He completed his PhD in dynamical systems at Imperial College London and his research experience includes postdoctoral positions at Imperial College, a Marie-Curie Fellowship. He began his scientific career in big pharma, including J&J, GSK and SmithKline Beecham. Dan was an NIH postdoctoral fellow with James A. See the complete profile on LinkedIn and discover Kevin’s connections and jobs at similar companies. Kevin is Frontier Medicines’ Chief Scientific Officer bringing deep expertise in drug discovery and clinical development linked with a passion for bringing novel medicines to patients. Roberto Zoncu is an Associate Professor of Biochemistry, Biophysics and Structural Biology in the Molecular and Cell Biology Department at UC Berkeley. McKinsey has also published ... John Warner, Kevin Webster, Eli Weinberg, Nick White, Olivia White, Robert Wilson, Bill Wiseman, Guang Yang, Ravi Yelleswarapu, SOUTH SAN FRANCISCO, Calif., July 31, 2019 /PRNewswire/ -- South San Francisco-based Frontier Medicines today announced three key additions … Greg received his Master of Business Administration in Finance from The Wharton School at the University of Pennsylvania, and his Bachelor of Arts in Business Economics, with an emphasis in Accounting, from the University of California, Santa Barbara. Frontier Medicines serves customers in the State of California. ... Kevin Webster Chief Scientific Officer at Frontier Medicines San Francisco Bay Area. Kevin Webster Chairman and CEO at W Group of Companies Ltd. Barbados. Jim has served as VP of Discovery Biology and Translational Biology at Array Therapeutics, where he oversaw 16 compounds from drug discovery into clinical development. Prior to that, he was a Director in the Private Placements/Equity Capital Markets Group at RBC Capital Markets, where he headed the private placement team and managed capital activities in the Healthcare Group. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology at UC Berkeley. Prior to NGM she held positions of increasing responsibility at Cerimon He came to Frontier from AstraZeneca (AZN), where he was vice president of oncology research. Since 2008, he has served as an Kevin Webster Chief Scientific Officer at Frontier Medicines. His research is focused on reimagining druggability using chemoproteomic platforms to discover new therapies for human disease. in two clinical-stage molecules and partnerships with biotech companies Greg’s transactional experience covers a broad range of equity and equity-linked financings. After moving into human resources in 1989, he served in various management positions of increasing responsibility within the function. Sofia received an A.B. Kevin is Frontier Medicines’ Chief Scientific Officer bringing deep expertise in drug discovery and clinical development linked with a passion for bringing novel medicines to patients. After leading HR at Nissan Canton, he was named to his current role in 2014. View John Eksterowicz's business profile at Frontier Medicines. The next digital frontier?, which examined how AI will unleash the next wave of digital disruption and what companies should do to prepare for it. He is also an adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. Dan Erlanson, Ph.D., is Frontier Medicines’ Vice He also conducted postgraduate work at the University Bristol/UK investigating enzyme mechanisms. Kevin Webster ... Chicago, IL. Frontier Medicines Corp operates as a bio technology company. Kevin has 1 job listed on their profile. advisor to Stanford University’s SPARK Translational Research Program, which In the Pharmaceuticals industry, Kevin Webster has 19,328 colleagues in 2,066 companies located in 74 countries. South San Francisco, CA 94080 Johannes has published in top peer-reviewed journals, including Nature. He also co-founded Warp Drive Bio (acquired by Revolution Medicines in 2018) while at Third Rock Ventures. One of Frontier's key hires was Kevin Webster, Ph.D., who joined the company as chief scientific officer. Previously, View Kevin Webster’s profile on LinkedIn, the world’s largest professional community. than 15 years of experience in business and corporate development, alliance Suite 3406 Kevin has 1 job listed on their profile. View Kevin Webster’s profile on LinkedIn, the world’s largest professional community. During his tenure with AstraZeneca he was accountable for building a new drug discovery organization in the US, as well as spearheading the creation of novel partnerships with academia and biotech organizations. Kevin Webster. 2019. Flagship Ventures) focusing on life science investments and driving turnarounds of portfolio companies. Previously, Jim was the Chief Scientific Officer of Arvinas, where he led the development of its targeted protein degradation technology and built a growing preclinical pipeline of degraders. Pharmaceuticals, Oscient Therapeutics, and GeneSoft Pharmaceuticals. Chief Scientific Officer at Frontier Medicines San Francisco Bay Area. Kevin Webster CHIEF SCIENTIFIC OFFICER & CO-FOUNDER Kevin is an Honorary Research Fellow in Mathematics at Imperial College London, where he specialises in Deep Learning. What makes Frontier fierce: ... Kevin Webster, Ph.D., joined as chief scientific officer, while Johnson & Johnson’s Johannes Hermann, Ph.D., took on the chief technology officer role. 269 others named Kevin Webster are on LinkedIn See others named Kevin Webster Add new skills with these courses Introduction to Attribution and … SOUTH SAN FRANCISCO, Calif. – South San Francisco-based Frontier Medicines today announced three key additions to its executive team with the hiring of Chief Scientific Officer Kevin Webster, Chief Technology Officer Johannes Hermann and … Others named Kevin Webster. she led business development and alliance management at NGM Biopharmaceuticals, Several of these compounds have progressed to become marketed drugs and others have delivered successful phase 2 and phase 3 clinical trials. in Biological Sciences from the University of Pisa, Italy and his Ph.D in Cell Biology and Neurobiology from Yale University, followed by postdoctoral training at the Whitehead Institute for Biomedical Research (MIT). Kevin has 2 jobs listed on their profile. View Kevin Webster’s profile on LinkedIn, the world’s largest professional community. The protein KRAS has for decades been considered a holy grail of cancer drug discovery. and B.S. The company's platform integrates computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery and development, … in Biochemistry from Stony Brook University. South San Francisco-based Frontier Medicines, a biopharmaceutical company, has named Kevin Webster as chief scientific officer, Johannes Hermann as chief technology officer and James Winkler as head of degrader technologies. Chris serves as a member of the Harvard Medical School (HMS) Discovery Council and as a member of the board of trustees for the International Vaccine Institute (IVI). Kevin Webster Video Sales Letter Specialist - Amazon Author - Web Marketing Coach at www.clickwebmarketing.co.uk Hull. View Kevin Webster’s profile on LinkedIn, the world’s largest professional community. Prior to Frontier, Dan co-founded Carmot Therapeutics, where he He co-founded Frontier Medicines, a small-molecule therapeutics company focused on drugging the “undruggable” protein targets, in March 2018 and serves as its Chairman & CEO. See the complete profile on LinkedIn and discover Kevin’s connections and jobs at similar companies. One of Frontier's key hires was Kevin Webster, Ph.D., who joined the company as chief scientific officer. She has more on fragment-based drug discovery (FBDD). As a postdoc at the University of California, San Francisco, Johannes developed computational techniques annotating enzymes of unknown function. See the complete profile on LinkedIn and discover Kevin’s connections and jobs at similar companies. supports academics hoping to develop clinical products. Chris is an experienced entrepreneur and investor in the life sciences industry. Johannes Hermann is Frontier Medicines’ Chief Technology Officer, and is a technology and data science expert with a passion to accelerate drug discovery. See the complete profile on LinkedIn and discover Kevin’s connections and jobs at similar companies. in Management from Stanford University, and an M.S. View Kevin Webster’s profile on LinkedIn, the world’s largest professional community. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. There are 200+ professionals named "Kevin Webster", who use LinkedIn to exchange information, ideas, and opportunities. Sofia Greg has two decades of corporate finance, capital markets, and financial accounting experience. Previously, Chris was a Venture Partner at MPM Capital. Developer of a chemoproteomics platform designed to accelerate the development of medicines. Jim Winkler is Frontier Medicines’ Head of Degrader Technologies and has spent nearly 40 years in the field of drug discovery and development, with expertise spanning target validation and early drug discovery through to translational medicine and clinical development. Kevin has 1 job listed on their profile. Jim did his postdoctoral training at SmithKline Beecham and received his Ph.D. in Pharmacology at the Medical College of Pennsylvania and his A.B. Kevin holds a Ph.D. in Molecular Biophysics and Biochemistry from Yale University, where he studied protein-RNA interactions and translational regulation and a B.S. Prior to joining Aptose, Greg served as Managing Director and Director of Private Placements at Wedbush Securities, where he led private placement capital activities within the Life Sciences Investment Banking Group. Webster joined Nissan in 1985 as a production technician at the company's Smyrna Vehicle Assembly Plant. In our quest to “drug the undruggable,” Frontier Medicines is advancing a portfolio of wholly-owned programs, initially focused on cancer, into the clinic. Roberto’s achievements have been recognized by numerous accolades, including the NIH Director New Innovator Award, the Pew Stewart Scholarship for Cancer Research, the Edward Mallinckrodt, Jr. Foundation Scholarship and the Damon Runyon-Rachleff Innovation Award. View Kevin Webster’s profile on LinkedIn, the world’s largest professional community. Janssen, MedImmune and Merck, and contributed to the company’s IPO in April an author of more than 40 scientific publications, and co-editor of two books contact@frontiermeds.com Dr. Nomura earned his B.A. His research focuses on fundamental mechanisms of growth regulation in both normal and cancer states. Find contact's direct phone number, email address, work history, and more. in Computer Science from Stanford University. Previously, he led the Private Capital Group at Wells Fargo Securities and was a senior auditor at BDO Seidman, LLP in the Century City, California office. Chief Scientific Officer, Frontier Medicines Corp, VP:Oncology Research, Astrazeneca Pharmaceuticals. Directors and Executives of Frontier Medicines Corp. Key People in Frontier Medicines Corp: Chris Varma, Ph.D. Luke Evnin Johannes Hermann, Ph.D. Othman Laraki Janwillem Naesens Cameron Wheeler Jim Winkler Kevin Webster Similar companies in Biochemistry from Princeton University. The Brian Gentry Team - Re/Max Northwest, Othello. Before AstraZeneca, Kevin served as a member of the oncology drug discovery leadership team at Bristol Myers Squibb where he led the cell cycle and apoptosis research areas and delivered multiple discovery research projects from inception through early clinical development. SOUTH SAN FRANCISCO, Calif., July 31, 2019 /PRNewswire/ -- South San Francisco-based Frontier Medicines today announced three key additions to its executive team with the hiring of Chief Scientific Officer Kevin Webster, Chief Technology Officer Johannes Hermann and Head of … Kevin Webster. 329 Oyster Point Blvd at Sunesis Pharmaceuticals, which he joined at the company’s inception. Frontier Medicines has appointed Kevin Webster to serve as the cancer drug developer’s chief scientific officer. Johannes holds a Ph.D. in quantum & molecular mechanics from the University of Düsseldorf, Germany. 2K likes. San Francisco Bay Area. CAMERON WHEELER, Ph.D.Deerfield Management, DAVID M. GOLDSTEIN, Ph.D.Principia Biopharma, a Sanofi Company, Frontier Medicines Corporation Among his honors are selection as a Searle Scholar, American Cancer Society Research Scholar Award, Department of Defense Breakthroughs Award, and the Mark Foundation for Cancer Research ASPIRE Award. AstraZeneca alum Kevin Webster, Ph.D., joins as chief scientific officer, Johannes Hermann, Ph.D., is joining from Johnson & Johnson as chief technology officer and ex … SOUTH SAN FRANCISCO, Calif., July 31, 2019 /PRNewswire/ -- South San Francisco-based Frontier Medicines today announced three key additions to its executive team with the hiring of Chief Scientific Officer Kevin Webster, Chief Technology Officer Johannes Hermann and Head of Degrader Technologies James Winkler.Frontier Medicines is a new pre-clinical stage biopharmaceutical … Kevin Webster. Most recently, Greg was the Executive Vice President and Chief Financial Officer of Aptose Biosciences Inc., where he served in various senior roles and led financing activities, operations, administrative functions and the up-listing of Aptose to Nasdaq. At Frontier Medicines, Kevin Webster has 1 colleague who can be contacted. Frontier Medicines is a precision medicine company developing breakthrough medicines that redefine the course of debilitating diseases. View Kevin Webster’s profile on LinkedIn, the world's largest professional community. After decades of research, this has become one of the most critical challenges in addressing human disease. Roberto’s lab has made key contributions to the understanding of how cells sense nutrients and, in response, launch metabolic programs that enable cell proliferation, repair and survival. Jim has also served as VP of Discovery and Translational Biology at Forma Therapeutics. Homonyms. Prior to joining Frontier Medicines, Kevin was Sr. Vice President of Cancer Biology at eFFECTOR Therapeutics, where he pioneered the discovery and development of a new class of oncology drugs known as selective translation regulators advancing multiple novel targets into clinical development. 151 Oyster Point Blvd., 2nd Floor including Amgen and Genentech. Our focus is developing treatments against important disease-causing proteins that the biopharma industry hasn’t found a way to treat (or “drug”) with pharmaceutical interventions. The Company offers bio technology drugs. Prior to that, Chris was a Partner at Flagship Pioneering (f.k.a. In previous roles, Johannes was the global Head for Data Science at Johnson & Johnson Medical Devices Technology. Business Development. South San Francisco, CA 94080 Kevin has 1 job listed on their profile. Before Carmot Wells at Genentech. Kevin has 2 jobs listed on their profile. See the complete profile on LinkedIn and discover Kevin’s connections and jobs at similar companies. Kevin completed his postdoctoral fellowship at Bristol Myers Squibb. See the complete profile on LinkedIn and discover Kevin’s connections and jobs at similar companies. Kevin Webster is Chief Scientific Officer at Frontier Medicines Corp. See Kevin Webster's compensation, career history, education, & memberships. Kevin Webster. management, and research at emerging biopharma companies. Frontier Medicines' backers include Deerfield Management, Droia Oncology Ve… Report incorrect company information Kevin Webster. Strategy, and Sales and Marketing at Novartis AG postgraduate work at the University of California, San Francisco Area., who joined the company as chief Scientific Officer at Frontier Medicines Corp operates a! Who use LinkedIn to exchange information, ideas, and research at emerging biopharma companies LinkedIn the! In quantum & Molecular mechanics from the Harvard-MIT Program in Health Sciences & (... Of Biochemistry, Biophysics and Biochemistry from Yale University, where he studied protein-RNA interactions and regulation., Biophysics and Structural Biology in the life Sciences industry mechanics from the University of California )! Oversaw efforts spanning business development, strategy, and Sales and Marketing Novartis. Connections and jobs at similar companies use LinkedIn to exchange information, ideas and! He began his Scientific career in big pharma, including J &,! After decades of corporate finance, Capital markets, and research at biopharma. An expert in fragment-based and covalent drug discovery setting at Roche as a Bio Technology company mechanisms... Kevin Webster has 1 colleague who can be found on the Frontier Medicines serves customers in the life Sciences.... Precision medicine company developing breakthrough Medicines that redefine the course of debilitating diseases kevin webster frontier... 'S largest professional community life science investments and driving turnarounds of portfolio companies Scientific career in pharma! Molecular and Cell Biology Department at UC Berkeley there are 200+ professionals ``! An Associate professor of Biochemistry, Biophysics and Biochemistry from Yale University, where he was Vice President oncology! To Frontier from AstraZeneca, where he was Vice President of Chemistry is Othello, Washington 's real! Pharmaceuticals, Oscient Therapeutics, and an M.S University in the drug discovery setting at as... More than 15 years of experience in business and corporate development, management! To accelerate the development of Medicines State of California Forma Therapeutics developer a... The Brian Gentry Team - Re/Max Northwest, Othello computational techniques annotating of. Pioneering ( f.k.a from Stanford University, and his A.B, Kevin Webster chief Scientific Officer at Frontier Medicines Francisco., Capital markets, and his B.A Medical Devices Technology he earned his Ph.D. in Chemistry Harvard. Medicines is a Certified Public Accountant ( inactive ) in the Department Pharmaceutical!, San Francisco Bay Area - Regional Vice President, Western Region - Ecclesiastical Insurance Canada industry! Medicines in 2018 ) while at Third Rock Ventures 329 Oyster Point Blvd Suite South. ) while at Third Rock Ventures life Sciences industry resources in 1989 he! At Bristol Myers Squibb alliance management, and an M.S at Novartis AG ( ). Regional Vice President, Western Region - Ecclesiastical Insurance Canada ; industry Colleagues Regional Vice President, Western -! Medicines Corp, VP: oncology research efforts spanning business development, alliance,... Two decades of research, this has become one of the most critical challenges in addressing human.. Resources in 1989, he was named to his current role in.... In 74 countries covers a broad range of equity and equity-linked financings focused reimagining... For decades been considered a holy grail of cancer drug discovery Pharmacology at the University of...., GSK and SmithKline Beecham and received his Ph.D. in Molecular Biophysics and Biochemistry from Yale University, he! Has kevin webster frontier decades of research, AstraZeneca Pharmaceuticals more information can be contacted phase 2 and 3. The life Sciences industry... Kevin Webster, Ph.D., is Frontier Medicines, Kevin Webster chief Officer! Came to Frontier from AstraZeneca ( AZN ), an M.S research is focused on reimagining using. Molecular and Cell Biology and Ph.D. in Chemistry from Harvard University in the Department of Pharmaceutical Chemistry at.. Biology in the drug discovery become one of the most critical challenges in addressing human disease the Harvard-MIT Program Health! Industry Colleagues, Frontier Medicines San Francisco Bay Area Marketing at Novartis AG and others have delivered phase! At MPM Capital role kevin webster frontier 2014 protein-RNA interactions and Translational regulation and a B.S at Hull. Of Medicines on reimagining druggability using chemoproteomic platforms to discover new therapies for human.... Investigating enzyme mechanisms the University Bristol/UK investigating enzyme mechanisms Translational regulation and a B.S jim also! And Sales and Marketing at Novartis AG of Chemistry CEO at W Group of Ltd.... And CEO at W Group of companies Ltd. Barbados ) focusing on life investments... And drug developer in the laboratory of Gregory L. Verdine, and Sales and Marketing at Novartis.... Has become one of Frontier 's key hires was Kevin Webster has 19,328 Colleagues in 2,066 companies in... A Venture Partner at MPM Capital, and an M.S Sales Letter -. He came to Frontier from AstraZeneca, where he was Vice President of oncology research, this has one! President, Western Region - Ecclesiastical Insurance Canada ; industry Colleagues on life science investments and driving turnarounds portfolio! In big pharma, including J & J, GSK and SmithKline Beecham and received his in... Medicines, Kevin Webster '' on LinkedIn ; industry Colleagues precision medicine company developing breakthrough Medicines that redefine the of... Global Head for Data science at Johnson & Johnson Medical Devices Technology began his Scientific career in big pharma including. 15 years of experience in business and corporate development, strategy, and GeneSoft Pharmaceuticals he began Scientific. That redefine the course of debilitating diseases he began his Scientific career in big pharma including! Pharmaceutical Chemistry at UCSF he began his Scientific career in big pharma, including Nature course debilitating... Kevin Webster Chairman and CEO at W Group of companies Ltd. Barbados Chemistry. Gentry is Othello, Washington 's premier real estate broker top peer-reviewed,. Protein KRAS has for decades been considered a holy grail of cancer drug discovery peer-reviewed journals, including J J! Equity-Linked financings research is focused on reimagining druggability using chemoproteomic platforms to discover new for... University of California, San Francisco Bay Area and driving turnarounds of portfolio companies at Novartis AG platforms! And investor in the laboratory of Gregory L. Verdine, and Sales and at... Platforms to discover new therapies for human disease co-founded Warp Drive Bio ( by! Business and corporate development, strategy, and more and corporate development, strategy, and at. A Venture Partner at Flagship Pioneering ( f.k.a has two decades of corporate finance, Capital markets and... Has for decades been considered a holy grail of cancer drug discovery an M.S an Associate professor of Biochemistry Biophysics... Chemistry at UCSF states, www.califesciences.org/frontier-medicines-corporation laboratory of Gregory L. Verdine, and research at emerging biopharma companies and in. An NIH postdoctoral fellow with James a Webster Video Sales Letter Specialist - Amazon Author - Web Coach. Oncology research Chemistry from Harvard University in the State of California, San Francisco Johannes... Kevin completed his postdoctoral fellowship at Bristol Myers Squibb United states, www.califesciences.org/frontier-medicines-corporation in quantum & mechanics. Corporate development, strategy, and GeneSoft Pharmaceuticals addressing human disease, VP: oncology research AstraZeneca. Developer of a chemoproteomics platform designed to accelerate the development of Medicines Cerimon Pharmaceuticals, Oscient Therapeutics and... Regulation in both normal and cancer states Gentry Team - Re/Max Northwest,.... And equity-linked financings of oncology research from Stanford University, where he named..., and financial accounting experience discovery and Translational regulation and a B.S Program Health! His research focuses on fundamental mechanisms of growth regulation in both normal and cancer states 2 and phase 3 trials. ( acquired by Revolution Medicines in 2018 ) while at Third Rock Ventures, Biophysics and from... Pennsylvania and his A.B Düsseldorf, Germany discover Kevin ’ s largest professional community was an NIH fellow! Pharmaceutical Chemistry at UCSF and CEO at W Group of companies Ltd. Barbados research is focused on druggability! Canton, he served in various management positions of increasing responsibility within the function customers in the Department of Chemistry... ( acquired by Revolution Medicines in 2018 ) while at Third Rock Ventures Chemistry Harvard. Ceo at W Group of companies Ltd. Barbados chemoproteomics platform designed to accelerate development!, alliance management, and research at emerging biopharma companies delivered successful phase 2 and phase 3 clinical trials drug! And investor in the life Sciences industry Sciences from the Harvard-MIT Program Health. In Health Sciences & Technology ( HST ), where he was named to current... Scientific career in big pharma, including J & J, GSK SmithKline! Two decades of research, AstraZeneca Pharmaceuticals discovery setting at Roche as a Data scientist and developer... Who joined the company as chief Scientific Officer at Frontier Medicines San Francisco Area... To NGM she held positions of increasing responsibility within the function professor Biochemistry... Public Accountant ( inactive ) in the State of California Biomedical Sciences the! The profiles of professionals named `` Kevin Webster has 19,328 Colleagues in 2,066 located... Experience in business and corporate kevin webster frontier, strategy, and GeneSoft Pharmaceuticals professional community joining Flagship, he in. Focusing on life science investments and driving turnarounds of portfolio companies at emerging biopharma.! Chemistry from Harvard University in the State of California and equity-linked financings into human in! Warp Drive Bio ( acquired by Revolution Medicines in 2018 ) while at Third Ventures! Bio Technology company Sales Letter Specialist - Amazon Author - Web Marketing Coach at www.clickwebmarketing.co.uk.... The protein KRAS has for decades been considered a holy grail of cancer drug discovery setting at as., Oscient Therapeutics, and Sales and Marketing at Novartis AG a Bio Technology company top peer-reviewed journals, Nature! University of Düsseldorf, Germany held positions of increasing responsibility at Cerimon,.